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Abstract Both NS3 protein (1007^1657) and its protease
moiety (NS3p, 1027^1207) were able to interact in vitro with
C1 Inhibitor (C1Inh) to give a 95-kDa Mr C1Inh cleavage
product similar to that obtained upon proteolysis by complement
protease C1s. High-Mr reaction products were also detected
after incubation of C1Inh with NS3 but not with NS3p; they
correspond to ester-bonded complexes from their hydroxylamine
lability. Similar reactivity of NS3 was observed upon incubation
with K2-antiplasmin. Serpin cleavage was prevented by treatment
of NS3 with synthetic serine protease inhibitors. This interaction
between viral NS3 and host serpins suggests that NS3 is likely to
be controlled by infected cell protease inhibitors.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Hepatitis C virus (HCV) is the major aetiologic agent of
non-A, non-B viral hepatitis [1,2]. The virus contains a single-
stranded, positive-sense RNA genome of approximately 9600
nucleotides length. The single polyprotein precursor of 3010^
3033 amino-acid residues is co- and post-translationally proc-
essed by cellular and viral proteases to yield the mature struc-
tural and non-structural proteins [2,3]. The structural proteins
comprise the core protein and two envelope glycoproteins, E1
and E2, which are processed by the signal peptidase of the
endoplasmic reticulum. Cleavage at the NS2/3 site is mediated
by a protease composed of NS2 and the amino-terminal one-
third of NS3. The serine protease (Ser-protease) NS3 is re-
sponsible for downstream cleavages in the non-structural re-
gion [4,5]. This protease activity is thought to be necessary for
the viral replication and appears as a valid target for antiviral
agents.
The N-terminal 180 amino acid region of NS3 has sequence
homologies with the active sites of Ser-proteases [6^8]. His-
1083, Asp-1107 and Ser-1165 (numbering according to their
locations in the polyprotein of HCV subtype J/HCV 1b [9])
are considered as a catalytic triad similar to other Ser-pro-
teases of the chymotrypsin family.
Ser-protease inhibitors or serpins are a large family of pro-
teins which have been identi¢ed from various sources such as
viruses and mammals [10^12]. They have been known for a
long time as inhibitors of extracellular Ser-proteases; recent
evidences suggest that a large number of serpins have intra-
cellular activities: Squamous cell carcinoma antigen 2 [13] or
cytotoxic cell proteinase inhibitor (PI)-6 [14] regulates the ly-
sosome/granule protease cathepsin G, PI-9 inhibits granule
granzyme B [15]. Moreover the myxoma virus serp2 or the
cowpox cytokine response modi¢er A are able to regulate the
caspase activity involved in apoptosis [16,17], indicating that
viral serpins are able to regulate target cell proteases.
The serpin inhibitory mechanism involves the formation of
an initial non-covalent complex followed by intermediate sub-
strate-like cleavage of the serpin reactive centre loop and a
tight serpin-protease covalent complex [11,12,18]. This com-
plex is formed when the C-terminal P1 residue of cleaved
serpin develops ester links with the active site Ser of the pro-
tease [11,12].
A control of pathogen protease by host cell serpin in the
virus-host cell relationship has not been reported as yet. It
becomes of interest to analyse a possible interplay between
serpins and the HCV Ser-protease NS3. We give evidence
that NS3 can interact with serpins such as C1 Inhibitor
(C1Inh) and K-2 antiplasmin (K2AP), with proteolysis of the
serpins and production of high-Mr complexes. This observa-
tion opens the way to pharmacological control on a new basis
in an attempt to block HCV proliferation.
2. Materials and methods
2.1. Construction of expression plasmids
NS3 and its protease N terminal moiety (NS3p) were expressed as
fusion proteins containing six His residues attached to the C terminus
for Ni-chelating a⁄nity puri¢cation. PCR-products were generated
using pTM1007 (isolate G01, type 1b) as a template [19] and the
oligonucleotide pairs: pair 1 (5Poligo: dCCCAAACAGTCGACTT-
CAG, 3Poligo: dTTTAGATCTCGTGACGACCTCCAGG) introduc-
ing a SalI site at the 5P-end and a BglII site at the 3P-end of the
sequence for the NS3 protein and pair 2 (5P oligo: dGGCGACCC-
ATGGCGCATATTACGGCC; 3Poligo: dGAAGACAGATCTCCG-
CATAGTGGTTTCC) introducing a NcoI site at the 5P-end and a
BglII site at the 3P-end of the sequence for NS3p. The PCR products
were ligated into the pQE60 vector (Qiagen, Paris, France) using the
NcoI and the BglII restriction sites, and for NS3 protein with the
addition of the NcoI-SalI 1300-bp fragment prepared from
pTM1007. The resulting plasmids encode the 1007^1657 sequence in
the polyprotein, corresponding to the whole NS3 protein with a 20-
residue N-terminus belonging to NS2 or the Ser-protease moiety of
NS3 (1027^1207).
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2.2. Expression and puri¢cation of recombinant NS3 and polypeptide
fragments
Expression was induced and proteins were puri¢ed as described in
[20]. Brie£y bacteria were centrifuged, the pellet was freezed at 380‡C,
resuspended in 12 ml sonication bu¡er (300 mM NaCl, 1 mM 2-
mercaptoethanol, 10 mM Na2HPO4, pH 7.4) and subjected to soni-
cation (6 Wm amplitude, energy 60, 3 cycles of 30 s each, Vibracell
Bioblock, Illkirch, France) on ice. The sonicate was separated on a gel
¢ltration column (Sephacryl-S300, Amersham Pharmacia Biotech, Sa-
clay, France) and each NS3 protein was puri¢ed on the Ni-NTA
a⁄nity matrix (Qiagen, Paris, France) using a 0^150 mM imidazole
gradient in the same bu¡er. Their purity was assessed from SDS-
PAGE analysis and microsequencing. Due to imidazole interference,
the protein in the samples was evaluated with ovalbumin as a stand-
ard on polyacrylamide gels. A single band was observed in puri¢ed
samples with MrV75 kDa andV25 kDa, respectively for NS3 and
NS3p (Fig. 1). The proteolytic activity was assessed on recombinant
NS5 protein (gift from Dr D. Vallari, Abbott, North Chicago, USA)
as described by Steinku«hler et al. [21] for a NS4A/B peptide.
2.3. Interaction NS3-serpins: incubation and analysis
C1Inh was puri¢ed according to Sim and Reboul [22], K2AP was
purchased from Stago (Asnie'res, France). The serpins were incubated
for 18 h at 37‡C with variable amounts of NS3 or NS3p, in 15 Wl 80
mM NaCl, 0.2 mM 2-mercaptoethanol, 0.1 mM ZnCl2, 10 mM imi-
dazole, 10 mM Na2HPO4, 10 mM Tris-HCl, pH 7.0. When indicated,
NS3 was pre-treated with di¡erent concentrations of Ser-protease in-
hibitors (NK-tosyl-Phe chloromethyl ketone (TPCK) or NK-tosyl-Lys
chloromethyl ketone (TLCK), Calbiochem, Meudon, France; di-iso-
propyl£uorophosphate (DFP) or phenylmethylsulfonyl £uoride
(PMSF), Sigma, Chesnes, France). In the case of deglycosylated
C1Inh, the serpin was pre-incubated with N-glycosidase F (Roche-
Boehringer, Meylan, France) in a glycosidase/C1Inh ratio of 3:100
(w/w) for 3.5 h at 37‡C in 1 mM EDTA, pH 8.0.
After incubation of NS3 with serpins, samples were subjected to
SDS-PAGE according to Laemmli [23]. For immunoblotting, the pro-
teins were transferred to Immobilon membranes (Millipore, St Quen-
tin-Yvelines, France) and subsequently incubated in 150 mM NaCl,
0.1% (w/v) Tween 20, 10 mM Tris-HCl, pH 7.5 with the peroxidase-
labelled anti-serpin antibody under stirring for 2 h at room temper-
ature. The membrane was washed (4U5 min) in 150 mM NaCl, 10
mM Tris-HCl, pH 7.5 and bands revealed with the 4-chloro-1-naph-
thol (Sigma, Chesnes, France). Alternatively a FITC-labelled antibody
was used and the membrane subjected to FluorImager densitometry
(Molecular Dynamics, Bondou£e, France).
3. Results
3.1. Proteolytic cleavage of C1Inh and formation of high-Mr
associations
To identify possible host serpin target for NS3, serpin-NS3
interaction was assessed by in vitro incubation of NS3 pro-
teins with serpin in concentration comparable to that ob-
served in extracellular £uids, followed by SDS-PAGE analysis
and anti-serpin immunoblotting. 1 Wg C1Inh was incubated
with 3 Wg NS3p (serpin/NS3p molar ratio of 1:1) or 1.2^4.2
Wg NS3 (serpin/NS3 1:1-1:3.5) as described in Section 2. The
samples were then subjected to SDS-PAGE and anti-C1Inh
immunoblot analyses. Fig. 2A shows that C1Inh is susceptible
to cleavage by NS3p with production of a band of MrV95-
kDa band similar to that obtained after a 15-min incubation
at 37‡C with 1.2 Wg C1s (C1Inh/C1s ratio of 1:1). The same
band is observed after incubation with NS3, the maximum
cleavage was obtained with serpin/NS3 molar ratio of 1:1
(Fig. 2B). In addition, high-Mr bands are clearly visible in
the assay samples. The proteolysis product is also detectable
after Coomassie blue staining (not shown). In the same con-
ditions, C1Inh was incubated with a recombinant NS3 protein
lacking the protease moiety (vNS3, sequence 1192^1458, a
kind gift from Dr G. Baccala, Lyon, France) as negative con-
trol. Fig. 2C shows that vNS3 does not cleave C1Inh. These
data indicate that C1Inh behaves as a substrate of NS3, with
also formation of high-Mr associations between NS3 and the
cleaved serpin.
The ester link between protease and serpin is labile to hy-
droxylamine at alkaline pH [24]. To analyse the high-Mr com-
plexes, the samples, prepared as above at the serpin/NS3 mo-
Fig. 1. Puri¢cation of the recombinant proteins. Samples were
loaded on a SDS-10% polyacrylamide gel and proteins stained by
Coomassie blue. Lanes: 1, Mr markers; 2, 3 and 4, fractions eluted
at 20 mM imidazole. A: Puri¢cation of NS3 protein. B: Puri¢cation
of NS3p.
Fig. 2. C1Inh-NS3 interactions: analysis by SDS-PAGE and anti-
C1Inh immunoblotting. The samples were loaded onto a SDS-7.5%
polyacrylamide gel and subsequently transferred onto Immobilon
membranes and incubated with a peroxidase-labelled anti-C1Inh
antibody. A: Incubation assay of C1Inh (1 Wg) with NS3p. Lanes:
2, C1Inh alone; 3, C1Inh+C1s (1.2 Wg); 4, C1Inh+NS3p (3 Wg).
B: Assay of C1Inh (1 Wg) with NS3. Lanes: 2, C1Inh/NS3 1:1;
3, C1Inh/NS3 1:2.5; 4, C1Inh/NS3 1:3.5; 5, C1Inh alone. C: Assay
of C1Inh (1 Wg) with vNS3. Lanes: 2, C1Inh+NS3p (3 Wg);
3, C1Inh alone; 4, C1Inh+vNS3 (2 Wg); 5, C1Inh+NS3 (1.2 Wg).
D: Assay of partially deglycosylated C1Inh (1 Wg) with NS3. Lanes:
2, C1Inh+NS3 (1.2 Wg); 3, deglycosylated C1Inh+NS3 (1.2 Wg);
4, deglycosylated C1Inh. Lanes 1: Mr markers.
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lar ratio of 1:1, were subjected to 1.2 M hydroxylamine (pH
9.0) or to 1.2 M NaCl, 20 mM Tris-HCl, pH 9.0 (control) for
2 h at 37‡C. Fig. 3 shows that high-Mr bands were decreased
with subsequent increase of the 95-kDa band intensity (lane
3), quite similarly to the reference C1Inh-C1s complexes (lane
6). These data indicate that ester linkage was involved in high-
Mr association between C1Inh and NS3.
3.2. Partially deglycosylated C1Inh is a target of NS3
Secreted C1Inh is highly glycosylated (26% carbohydrate
w/w). Underglycosylated intracellular forms of C1Inh [25]
are likely to coexist with NS3 in the cells infected by HCV.
It was thus of interest to investigate if partially deglycosylated
C1Inh could in vitro interact with NS3. C1Inh was treated by
N-glycosidase F as described in Section 2 before incubation
with NS3 (serpin/NS3 molar ratio of 1:1) as above. Fig. 2D
shows that the underglycosylated C1Inh was cleaved in a
V80-kDa band with also formation of high Mr-bands upon
incubation with NS3, as with C1s, indicating that the degly-
cosylated C1Inh is also able to interact with NS3.
3.3. E¡ects of synthetic protease inhibitors on the NS3-C1Inh
interaction
To assess the proteolysis of C1Inh by NS3, the protease was
preincubated in the presence of four synthetic Ser-protease
inhibitors (TPCK, TLCK, DFP and PMSF) before addition
of C1Inh: samples of 1.2 Wg NS3 were treated with 0.05^0.2
mM TPCK, 0.2^2 mM TLCK, 5^10 mM DFP or 2 mM
PMSF for 30 min at 37‡C before incubation with 2 Wg
C1Inh in the same conditions as above. SDS-PAGE and
anti-C1Inh immunoblot analyses of the samples showed that
the proteolysis of C1Inh by NS3 was susceptible to 10 mM
DFP, 0.2^2 mM TLCK (Fig. 4, lanes 2, 5 and 6) and 2 mM
PMSF (not shown) and partially susceptible to 0.2 mM
TPCK (Fig. 4, lane 8). These data con¢rm that the NS3 pro-
teolysis of C1Inh is due to the Ser-protease NS3.
3.4. Interactions of NS3 with K2 antiplasmin
To check that the reactivity of NS3 was not restricted to
C1Inh, samples of K2AP, another serpin, were incubated with
NS3 (serpin/NS3 molar ratios of 0.5:1 to 5:1) in the above
conditions and subsequently analysed by SDS-PAGE and
anti-K2AP immunoblot. Fig. 5 shows that K2AP was also
susceptible to cleavage by NS3 with production of a band
of MrV65 000 and with also formation of high-Mr com-
plexes.
The same procedure was applied to K1-anti-trypsin and
ovalbumin (a non-inhibitory serpin) without evidence for their
cleavage by NS3 (not shown). These data indicate that NS3 is
able to interact with several but not all serpins.
4. Discussion
Reactive centres of serpins consist of a mobile loop with P1-
PP1 residues behaving as targets for a number of proteases.
NS3 interacts with two serpins, C1Inh and K2AP with pro-
duction of fragment of similar size to those produced upon
cleavage by other proteases. Formation of intermediate high-
Mr complexes characteristic of the serpin activity, according
to a structural model proposed recently [18], has also been
reported. This suggests that the reactive centre loops of
C1Inh and K2AP are two other possible substrates for NS3
beyond the already known cleavages of the HCV polyprotein
[4,5,26]. This cleavage of C1Inh and K2AP is achieved by the
Ser-protease site of NS3, from its inhibition pattern by speci¢c
synthetic inhibitors which is similar to the inhibition pattern
of NS3-catalysed HCV polypeptide cleavage [21]. The obser-
vation of high-Mr association is the best evidence for a con-
trol of NS3 proteolytic activity by serpins. High-Mr associa-
tions were only detected after incubation with complete NS3
Fig. 5. K2AP-NS3 interaction: analysis by SDS-PAGE and immu-
noblotting. The samples were loaded onto a SDS-7.5% polyacryl-
amide gel and transferred onto an Immobilon membrane and incu-
bated with a peroxidase-labelled anti-K2AP antibody. Lanes: 1, Mr
markers; 2, K2AP alone (0.5 Wg); 3, K2AP+NS3 with K2AP/NS3 ra-
tio of 5:1; 4, K2AP/NS3 2:1; 5, K2AP/NS3 1:1; 6, K2AP/NS3
0.5:1.
Fig. 4. Susceptibility of proteolysis of C1Inh by NS3 to Ser-protease
inhibitors. Lanes: 1, C1Inh (1 Wg)+NS3 (1.2 Wg); 2, ido after incu-
bation of NS3 with 10 mM DFP; 3, 5 mM DFP; 4, 2 mM TLCK;
5, 0.2 mM TLCK; 6, 0.2 mM TPCK; 7, 0.05 mM TPCK.
Fig. 3. E¡ect of hydroxylamine on high-Mr associations with
C1Inh. The samples were loaded onto a SDS-7.5% polyacrylamide
gel, transferred onto an Immobilon membrane, incubated with a
FITC-labelled antibody and subjected to an FluorImager. Lanes: 1,
C1Inh alone (1.5 Wg); 2, C1Inh (1.5 Wg)+NS3 (2 Wg); 3, ido and
subjected to 1.2 M hydroxylamine pH 9.0; 4, ido to 1.2 M NaCl
pH 9.0; 5, C1Inh (1.5 Wg)+C1s (2 Wg) and subjected to 1.2 M NaCl
pH 9.0; 6, ido to 1.2 M hydroxylamine pH 9.0.
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and not with NS3p, which probably re£ects a role of the large
C-terminal helicase moiety of NS3 in stabilising serpin-pro-
tease complexes. This could be related to a functional inter-
dependence between the two protease and helicase moieties of
NS3, as it has been suggested by the polynucleotide modula-
tion of the protease activity [27].
These results with both C1Inh and K2AP represents the ¢rst
in vitro observation between puri¢ed host serpins and the
HCV NS3 protease. As the two serpins are synthesised and
secreted mainly by hepatocytes, their role in hepatitis C can be
questioned: is a de¢ciency of a serpin associated with in-
creased risk for hepatitis C? Up to now, dealing with another
serpin, K1-antichymotrypsin, a relationship between its de¢-
ciency and chronic HCV infection has not been described,
although low plasma levels of K1-antichymotrypsin were fre-
quently observed [28]. Our observation however supports the
hypothesis that HCV NS3 produced by infected hepatocytes is
likely to be regulated by host cell proteins such as serpins.
This hypothesis is currently explored in an in vitro system
of cultured hepatoma cells producing C1Inh in which HCV
NS3 is expressed.
Control of HCV NS3 protease by host serpins can be
viewed as a general mechanism where serpins of target cells
act as sentinels of innate immunity against viral infections. It
appears thus of interest to re¢ne anti-HCV therapy by pro-
moting or reinforcing interaction of the serpins described
here, and eventually of other serpins, with the HCV NS3
protease inside hepatocytes or other targets of the virus.
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